Rigel Pharmaceuticals | RIGL - Debitur Perdagangan





Debitur Perdagangan Perubahan Tanggal
Agenus USD 22.44M 1.14M 2025-12
Amgen USD 9.14B 432M 2026-03
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 218.87M 212.05M 2025-12
AstraZeneca USD 17.88B 1.17B 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Celldex Therapeutics USD 2.02M 1.92M 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Heron Therapeutics USD 89.59M 8.54M 2025-12
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 74M 8M 2026-03
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
Ligand Pharmaceuticals USD 58.1M 15.98M 2025-09
MacroGenics USD 13.37M 55.86M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Pfizer USD 15.84B 2.27B 2025-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Ultragenyx Pharmaceutical USD 158M 45.46M 2025-12
Veracyte USD 44.66M 3.17M 2025-12